A Dutch multinational pharmaceutical company is looking for licensing partners of its human monoclonal antibody production platforms in the field of immuno-oncology or immunologic diseases.
A Dutch multinational pharmaceutical company focusses on therapeutic product development in the fields of immuno-oncology and immunologic diseases, using its proprietary transgenic mouse platforms producing human antibodies: common and heavy-chain only antibodies. The company is looking for partners within immuno-oncology or immunologic diseases to license the human antibody platform to, or for product co-development partnering. A research cooperation agreement or a license agreement is foreseen
The company is seeking collaboration with other companies (SME’s) and academia related to its expertise: i. pharmaceutical product developer: in-licensing of the transgenic human mAb platform or co-development. ii. academic institute: in-licensing of the transgenic human mAb platform or co-development.
A multinational pharmaceutical biotech company, having premises in Europe-the Netherlands, develops innovative therapies for cancer and immune-driven diseases. The company has a growing clinical portfolio and an emerging pipeline of next generation biologics based on its two patented transgenic mouse platforms for producing fully human antibodies. Therapeutic monoclonal antibody (mAb) is one of the fastest growing segments of the global pharmaceutical industry. More and more approved mAbs are fully human antibodies. One of the major engines to generate fully human antibodies is genetically engineered mice technology. The company is building its proprietary pipeline internally, through collaborations with co-development partners, as well as through selected preclinical and clinical stage asset acquisitions. The company also licenses the platforms to companies and academic institutions through its subsidiary. The company is looking for licensing partners to license-out its human antibody producing transgenic mouse platforms within the field of immuno-oncology or immunologic diseases. For both commercial and academic partners also co-development opportunities and single-target evaluation programs are available based on these antibody platforms. These provide efficient, low risk high value, pharmaceutical compliant means to develop and produce highly advanced mAb therapeutics. The company is looking preferably for other European product developing entities within immuno-oncology or immunologic diseases to license the human antibody platform to, or for product co-development partnering using the antibody platform. A research cooperation agreement or a license agreement is foreseen.
Advantages and innovations
The transgenic mouse platforms yield either i. human common monoclonal antibodies (mAb) or ii. human heavy-chain only mAbs. i. The common mAbs display: - normal antibody and affinity maturation in vivo - intact somatic hypermutation - pM to nM affinity ranges - no lead optimization required - no humanisation step required - preventing affinity-reduction risks - timely lean production These mAbs are used in marketed therapeutics as e.g. checkpoint inhibitors and other applications. ii. The human heavy-chain only mAbs display: - high affinity, solubility and stability - good expression - non-aggregate in vivo - no lead optimization required - no humanisation step required - preventing affinity-reduction risks - timely lean production These mAbs are used for generating e.g. single-domain Abs, bispecific Abs, and chimeric-antigen receptor (CAR) structures like CAR-T or CAR-NK.
Already on the market
Intellectual Property Rights (IPR)
Patents granted,Trade Marks,Exclusive Rights
Register your interest
How it works
- Tell us about yourself
- We’ll discuss with you
- We put the right partners in touch
EEN help you find the right partner, rather than you going it alone.
Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.
These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.
Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.
First we need to check you’re human.
Thank you for verifying your email. We have sent you a confirmation email containing a 6 digit verification code to unlock the form below